Core Points - The legal opinion letter is regarding the second extraordinary general meeting of shareholders of Ningxia Zhongke Biotechnology Co., Ltd. in 2025 [1] - The law firm confirms that the meeting's convening, procedures, and voting processes comply with relevant laws and regulations [2][5] Group 1: Meeting Procedures - The company’s board of directors announced the meeting details, including time, location, and voting methods, through the Shanghai Stock Exchange [2][3] - The meeting utilized both on-site and online voting, with specific time slots for shareholders to cast their votes [3] Group 2: Attendance and Qualifications - The meeting was convened by the board of directors, with Mr. Zhu Canti serving as the chairperson [4] - A total of 293 shareholders or their representatives attended the meeting, representing 240,960,322 shares, which is 35.18% of the total voting shares [4] Group 3: Voting Results - The voting process was conducted in accordance with legal and regulatory requirements, with results verified by the law firm [5][6] - The first proposal received 239,566,822 votes in favor, accounting for 99.4216% of the total votes cast [5] - Subsequent proposals also passed with significant majority support, with the highest approval rate being 99.6722% for one of the proposals [6][7] Group 4: Conclusion - The law firm concludes that all aspects of the meeting, including convening, attendance, and voting, were conducted in compliance with applicable laws and the company's articles of association [7]
ST宁科: 关于宁夏中科生物科技股份有限公司2025年第二次临时股东会法律意见书